Marc Lacroix (biochemist) explained

Birth Name:Marc Guy Albert Marie Lacroix
Birth Date:28 April 1963
Birth Place:Verviers, Belgium
Education:University of Liège
Fields:Biochemistry
Known For:Breast cancer
Workplaces:Institut Jules Bordet, Belgium

Marc Guy Albert Marie Lacroix (in French pronounced as /maʁk lakʁwa/; born 28 April 1963 in Verviers, Wallonia, Belgium) is a biochemist (educated at University of Liège) and a researcher who specializes in breast cancer biology, metastasis and therapy.[1] [2] [3] [4] [5] [6] [7] [8] [9]

He works at Institut Jules Bordet (Brussels, Belgium). He lives in Baelen

Earlier work

Breast cancer cells (BCC) frequently metastasize to the skeleton, where they lead to tumor-induced osteolysis and subsequent morbidity. Marc Lacroix has investigated the interrelationships between BCC and bone cells (osteoblasts, the bone-building cells, and osteoclasts, the bone-degrading cells). With colleagues, he discovered that BCC produce soluble factors increasing osteoclast activity, notably interleukin-11, the production of which is reduced by the cyclooxygenase inhibitor aspirin.[10] [11] [12] BCC also reduce the proliferation of osteoblasts and their production of collagen, the main protein component of bone.[13] [14] [15] Marc Lacroix also examined the response BCC to the anti-osteolytic agent calcitonin[16] [17]

In close collaboration with Prof. Guy Leclercq (Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Belgium), Marc Lacroix has studied various aspects of estrogen receptor biology, ligand-binding and transcriptional activity, and life-cycle.[18] [19] [20] [21] [22] [23] [24] [25] [26]

Recent work

The amount of data on breast cancer available for the scientific and medical community is growing rapidly. According to PubMed, a search engine offering access to the MEDLINE database of citations and abstracts of biomedical research articles, 7918 papers containing the expression «breast cancer» were published in 2006. Their number was 3592 in 1996, 1455 in 1986 and only 626 in 1976. In general, the older information is overlaid by more recent data and forgotten to some extent. In 2004, Lacroix and colleagues collected and assembled data from hundreds of articles related to the biology, pathology and genetics of in situ, invasive and metastatic breast cancers. These papers were covering a time period of about 25 years. Lacroix et al. concluded that despite undergoing increasing genetic alteration, most individual breast cancers rather surprisingly maintain their phenotype when they evolve from in situ to the metastatic state.[27] This conclusion was in opposition to a progression model widely accepted at that time, which was suggesting that carcinoma in situ could evolve into invasive carcinoma and subsequently produce metastases through an accumulation of molecular abnormalities possibly allowing extensive phenotype changes and subsequent gain of aggressiveness.

Bibliography: collaborative books – invited chapters

Bibliography: books

References

Over the years, Marc Lacroix has been refereeing for several international scientific and clinical journals:

External links

Notes and References

  1. B . Siwek . Larsimont D . Lacroix M . Body JJ . Establishment and characterization of three new breast-cancer cell lines . International Journal of Cancer . 1998 . 76 . 677–683 . 9610725 . 10.1002/(SICI)1097-0215(19980529)76:5<677::AID-IJC11>3.0.CO;2-1 . 5. free .
  2. M . Lacroix . Zammatteo N . Remacle J . Leclercq G. . A low-density DNA microarray for analysis of markers in breast cancer . International Journal of Biological Markers . 2002 . 17 . 5–23 . 11936587 . 1. microarray . 10.1177/172460080201700102 . free .
  3. M . Lacroix . Leclercq G. . Relevance of breast cancer cell lines as models for breast tumours: an update . . 2004 . 83 . 249–289 . 14758095 . 10.1023/B:BREA.0000014042.54925.cc . 3. 207628369 .
  4. M . Lacroix . Haibe-Kains B . Hennuy B . Laes JF . Lallemand F . Gonze I . Cardoso F . Piccart M . Leclercq G . Sotiriou C. . 21227327 . Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes . Oncology Reports . 2004 . 12 . 701–707 . 15375488 . 4 . 10.3892/or.12.4.701 .
  5. M . Lacroix . Leclercq G . BreastMed Consortium . The "portrait" of hereditary breast cancer . . 2005 . 89 . 297–304 . 15754129 . 10.1007/s10549-004-2172-4 . 3. 23327569 .
  6. De Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J . Molecular characterization of breast cancer cell lines by a low-density microarray . . 2005 . 27 . 881–892 . 16142302 . 4.
  7. M . Lacroix . Toillon RA . Leclercq G. . P53 and breast cancer, an update . Endocrine-Related Cancer . 2006 . 13 . 293–325 . 16728565 . 10.1677/erc.1.01172 . 2. free .
  8. M . Lacroix. . Significance, detection and markers of disseminated breast cancer cells . Endocrine-Related Cancer . 2006 . 13 . 1033–1067 . 17158753 . 10.1677/ERC-06-0001 . 4.
  9. M . Lacroix. . Persistent use of "false" cell lines . International Journal of Cancer . 2008 . 122 . 1–4 . 17960586 . 10.1002/ijc.23233 . 1. free .
  10. M . Lacroix . Siwek B . Marie PJ . Body JJ. . Production and regulation of interleukin-11 by breast cancer cells . Cancer Letters . 1998 . 127 . 29–35 . 9619855 . 10.1016/S0304-3835(97)00542-9 . 1–2. Interleukin 11 .
  11. Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ . The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and-11 . Anticancer Research . 1999 . 19 . 2997–3006 . 10652584 . 4B.
  12. C . Sotiriou . Lacroix M . Lespagnard L . Larsimont D . Paesmans M . Body JJ. . Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases . Cancer Letters . 2001 . 169 . 87–95 . 11410329 . 10.1016/S0304-3835(01)00524-9 . 1.
  13. M . Lacroix . Siwek B . Body JJ. . Effects of secretory products of breast cancer cells on osteoblast-like cells . . 1996 . 38 . 209–216. 8861839 . 10.1007/BF01806675 . 2. osteoblast . 25572056 .
  14. B . Siwek . Lacroix M . DePollak C . Marie P . Body JJ. . Secretory products of breast cancer cells specifically affect human osteoblastic cells: Partial characterization of active factors . Journal of Bone and Mineral Research . 1997 . 12 . 552–560. 9101366 . 10.1359/jbmr.1997.12.4.552 . 4. 46565128 . free .
  15. M . Lacroix . Lacroix M . Marie PJ . Body JJ. . Protein production by osteoblasts: modulation by breast cancer cell-derived factors . . 2000 . 61 . 59–67 . 10930090 . 10.1023/A:1006408916224 . 1. 9512363 .
  16. M . Lacroix . Body JJ. . Regulation of c-fos and c-jun expression by calcitonin in human breast cancer cells . Calcified Tissue International . 1997 . 60 . 513–519. 9164825 . 10.1007/s002239900273 . 6. 34337293 .
  17. M . Lacroix . Siwek B . Body JJ. . Breast cancer cell response to calcitonin: Modulation by growth-regulating agents . European Journal of Pharmacology . 1998 . 344 . 279–286. 9600664 . 10.1016/S0014-2999(97)01578-1 . 2–3. calcitonin .
  18. L . Jin . Borras M . Lacroix M . Legros N . Leclercq G. . Antiestrogenic activity of 2 11-beta-estradiol derivatives on MCF-7 breast cancer cells . . 1995 . 60 . 512–518. 8539793 . 10.1016/0039-128X(95)00079-6 . 8. 9007067 .
  19. M . Borras . Lacroix M . Legros N . Leclercq G. . Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers . Cancer Letters . 1997 . 120 . 23–30. 9570382 . 10.1016/S0304-3835(97)00285-1 . 1.
  20. Y . Maaroufi . Lacroix M . Lespagnard L . Journe F . Larsimont D . Leclercq G. . Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis . Breast Cancer Research . 2000 . 2 . 444–454 . 11056692 . 10.1186/bcr92 . 6 . 13922 . free .
  21. M . Lacroix . Querton G . Hennebert P . Larsimont D . Leclercq G. . Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison . . 2001 . 67 . 263–271 . 11561772 . 10.1023/A:1017946810277 . 3. 631103 .
  22. A . Rivas . Lacroix M . Olea-Serrano F . Laios I . Leclercq G . Olea N. . Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells . Journal of Steroid Biochemistry and Molecular Biology . 2002 . 82 . 45–53 . 12429138 . 10.1016/S0960-0760(02)00146-2 . 1. 9619137 .
  23. M . Lacroix . Leclercq G. . About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer . Molecular and Cellular Endocrinology . 2004 . 219 . 1–7 . 15149721 . 10.1016/j.mce.2004.02.021 . 1–2. 38557047 .
  24. Toillon RA, Magné N, Laios I, Lacroix M, Duvillier H, Lagneaux L, Devriendt D, Van Houtte P, Leclercq G . Interaction between estrogen receptor α, ionizing radiation and (anti-) estrogens in breast cancer cells . . 2005 . 93 . 207–215 . 16136271 . 10.1007/s10549-005-5148-0 . 3. 6016940 .
  25. G . Leclercq . Lacroix M . Laïos I . Laurent G. . Estrogen receptor α: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells . . 2006 . 6 . 39–64 . 16475975 . 10.2174/156800906775471716 . 1. 10.1.1.475.5425 .
  26. Toillon RA, Magné N, Laïos I, Castadot P, Kinnaert E, Van Houtte P, Desmedt C, Leclercq G, Lacroix M . Estrogens decrease gamma-rays induced senescence and maintain cell cycle progression in breast cancer cells independently of p53 . International Journal of Radiation Oncology, Biology, Physics . 2007 . 67 . 1187–1200 . 17336220 . 4 . 10.1016/j.ijrobp.2006.11.040.
  27. M . Lacroix . Toillon RA . Leclercq G. . Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics . Endocrine-Related Cancer . 2004 . 11 . 497–522 . 15369451 . 10.1677/erc.1.00758 . 3. free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Marc Lacroix (biochemist)".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.